Program

TOP>Program

Pipeline

  Screening Lead
Development
Formulation IND Enabling Phase Ⅰ Phase Ⅱ Phase Ⅲ Approval
TMS-007
Acute Ischemic Stroke
     Ongoing
TMS-008
Kidney/Liver
Diseases
  Ongoing
TMS-008
Autoimmune Diseases
(Acute phase)
  Ongoing
TMS-009
Kidney/Liver
Diseases
  Ongoing
TMS-009
Autoimmune Diseases
(Acute phase)
  Ongoing
SMTP Oral
Chronic
Inflammatory Diseases
 Planned

TMS-007

TMS develops its lead compound TMS-007, which belongs to SMTP compound family, indicating Acute Ischemic Stroke (AIS). AIS causes approximately 66,000 deaths each year and is the biggest reason to result in disability, both in Japan. AIS is also the fifth largest cause of death in US and second largest worldwide. The only approved drug for AIS, recombinant tissue plasminogen activator (rt-PA), is believed to be used for only 5-10% of AIS patients in developed countries mainly because its timing is limited within 4.5 hours after onset. TMS-007 is expected to be used until 12 or 24 hours after onset resulting in availability in much larger patient population.
TMS-007 is under double-blind, placebo-controlled, randomized Phase IIa clinical trial testing safety and efficacy for AIS patients within 12 hours after onset. TMS entered into an option agreement with Biogen pertaining to development and commercialization of TMS-007.

TMS-007 Clinical Concept Diagram

Other SMTP Compounds

TMS is developing other SMTP compounds primarily leveraging SMTP's anti-inflammatory activities.